Open AccessT-cell proliferative response to human papillomavirus type 16 peptides: relationship to cervical intraepithelial neoplasia
Author(s) -
Mayumi Nakagawa,
Daniel P. Stites,
Sepideh Farhat,
Allen Judd,
AnnaBarbara Moscicki,
AJ Canchola,
Joan F. Hilton,
Joel M. Palefsky
Publication year - 1996
Publication title -
clinical and diagnostic laboratory immunology
Language(s) - English
Resource type - Journals
eISSN - 1098-6588
pISSN - 1071-412X
DOI - 10.1128/cdli.3.2.205-210.1996
Subject(s) - cervical intraepithelial neoplasia , colposcopy , medicine , cervical cancer , immune system , disease , immunology , antigen , oncology , gynecology , cancer
The incidence of human papillomavirus (HPV)-related cervical intraepithelial neoplasia (CIN) and cervical cancer is increased with immunodeficiency, but the role of immune response, including cell-mediated immunity, in disease prevention is not well understood. In this study, T-cell proliferative responses to six synthetic peptides with predicted immunogenic determinants from the HPV-16 E4, E6, E7, and L1 open reading frames were analyzed in 22 sexually active women with new-onset CIN and 65 sexually active women without cervical disease, characterized by cytology, colposcopy, and HPV testing. T-cell proliferative responses were demonstrated to all six HPV-16 peptides. Although not statistically significant, rates of reactivity to E6 (24-45) were higher among sexually active women without disease (26%) than among women with current CIN (7%), as was the overall number of peptides stimulating a response. Women with CIN may not respond to selected HPV antigens as well as women without disease do.